PCR testing company Vela Diagnostics reported on Tuesday the receipt of the US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the ViroKey SARS-CoV-2 RT-PCR Test v2.0 to detect SARS-CoV-2 in nasopharyngeal and oropharyngeal swabs.
Vela Diagnostics said its automated probe-based reverse transcription PCR test detects SARS-CoV-2, the coronavirus responsible for COVID-19. Laboratories in the US certified under the Clinical Laboratory Improvement Amendments can use the test for COVID-19 detection.
According to the company, the ViroKey SARS-CoV-2 RT-PCR Test v2.0 is an automated probe-based reverse transcription PCR test optimized for a workflow consisting of its Sentosa SX101 and the Sentosa SA201 instrument (or ABI 7500 Fast Dx). The automated test enables high throughput testing of up to 46 samples in a single run, with reduced hands-on time.
In addition, the company's ViroKey SARS-CoV-2 RT-PCR Test v2.0 has received the CE mark and Provisional Authorisation from the Singapore Health Sciences Authority.
GSK hepatitis B therapy bepirovirsen gains FDA priority review and breakthrough designation
Xcovery and EVERSANA partner for US commmercialisation of lung cancer drug Ensacove
Novartis secures European approval for remibrutinib in chronic spontaneous urticaria
Evofem signs exclusive deal to expand SOLOSEC distribution in sub-Saharan Africa
GSK secures US and EU fast-track designations for efimosfermin in MASH
AstraZeneca secures US approval for Saphnelo self-administration in lupus treatment
Abbott presents late-breaking clinical data on treating heart rhythm disorders
Novartis receives positive CHMP opinion for Itvisma in spinal muscular atrophy